GERMANY AND CANADA PRICE CONTROLS:

COUNCIL FOR AFFORDABLE
HEALTH COVERAGE

A STEEP PRICE TO PAY

Most Favored Nation (MFN) pricing would import government price controls from countries like Germany and Canada.

While these systems may lower prices, they often delay access to new medicines and risk reducing innovation, limiting treatment availability, and weakening U.S. global competitiveness.

WHAT PRICE CONTROLS COST PATIENTS

GERMANY

80%

of new medicines are available in Germany, vs. 92% in the U.S.

CANADA

90 wks

longer wait than Americans for new, life-saving drugs.

WHY THESE SYSTEMS FAIL PATIENTS

GERMANY

GOVERNMENT "VALUE" JUDGMENTS

A federal committee, not physicians or patients, decides whether a drug has "added benefit."

GERMANY

LAUNCH DELAYS & WITHDRAWALS

Rather than accept forced prices, manufacturers delay launches or pull medicines from the market.

CANADA

LAYERS OF BUREAUCRACY

Every drug faces multiple reviews, price ceilings, and separate negotiations, delaying access to patients.

CANADA

COVERAGE BY POSTAL CODE

Each province decides on its own whether to cover a drug, so access depends on where you live.

THE UNITED STATES DIFFERENCE

Americans access the world's newest medicines first, and the U.S. leads the world in developing them. MFN pricing would trade that advantage away for the delays, withdrawals, and coverage denials that define Germany's and Canada's systems.